Cancer genetics: Risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer

Cancer Treatment and Research

Volumn 156, Issue , 2010, Pages 69-85

  Shulman, Lee P ^a   Dungan, Jeffrey S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; EPITHELIAL OVARIAN CANCER; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HEREDITARY BREAST AND OVARIAN CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; MISMATCH REPAIR; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SITE SPECIFIC OVARIAN CANCER;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 77956358319     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6518-9_6     Document Type: Review

References (31)

1. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009;3:138-50.
2. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009;3:97-137.
3. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415-28.
4. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76:284-90.
5. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer. 2002;2:113-23.
6. Danforth KN, Tworoger SS, Hecht JL, et al. Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control. 2007;18:517-23.
7. Stratton JF, Pharoah P, Smith SK, et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998;105:493-9.
8. Werness BA, Eltabbakh GH. Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. Int J Gynecol Pathol. 2001;20:48-63.
9. Auranen A, Pukkala E, Makinen J, et al. Cancer incidence in the first degree relatives of ovarian cancer patients. Br J Cancer. 1996;74:280-4.
10. McGuire V, Felberg A, Mills M, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 mutations. Am J Epidemiol. 2004;160:613-18.
11. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Nat Cancer Inst. 2002;94:1773-9.
12. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16:15-23.
13. A. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009;113:1027-37.
14. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157-62.
15. Ramus SJ, Harrington PA, Pye C, et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat. 2007;28:1207-15.
16. Bewtra C, Watson P, Conway T, et al. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol. 1992;11:180-7.
17. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222-33.
18. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379-88.
19. Whittemore AS, Gong G, Imyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from 3 US population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60:496-504.
20. Satogapan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8:3776-81.
21. Antoniou AC, Gayther SA, Stratton JF, et al. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18:173-90.
22. Pal T, Permuth-Wey J, Sellers TA. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer. 2008;113:733-42.
23. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444-9.
24. Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet. 1999;23:142-4.
25. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812-16.
26. Malander S, Rambech E, Kristoffersson U, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol. 2006;101:238-43.
27. South SA, Vance H, Farrell C, et al. Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers. Cancer. 2009;115:324-33.
28. Russo A, Calo V, Bruno L, et al. Hereditary ovarian cancer. Crit Rev Oncol Hematol. 2009;69:28-44.
29. Cederquist K, Emanuelsson M, Wiklund F, et al. Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. Clini Genet. 2005;68:533-41.
30. Ozanne EM, Loberg A, Hughes S, et al. Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast. 2009;15:155-62.
31. Prucka SK, McIlvried DE, Korf BR. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example. Med Princ Pract. 2008;17:173-89.